The Role of Cardiac Myosin Binding Protein C3 in Hypertrophic Cardiomyopathy-Progress and Novel Therapeutic Opportunities

Iman A. Mohamed, Navaneethakrishnan Krishnamoorthy, Gheyath K. Nasrallah, Sahar Da'as

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Hypertrophic cardiomyopathy (HCM) is a common autosomal dominant genetic cardiovascular disorder marked by genetic and phenotypic heterogeneity. Mutations in the gene encodes the cardiac myosin-binding protein C, cMYBPC3 is amongst the various sarcomeric genes that are associated with HCM. These mutations produce mutated mRNAs and truncated cMyBP-C proteins. In this review, we will discuss the implications and molecular mechanisms involved in MYBPC3 different mutations. Further, we will highlight the novel targets that can be developed into potential therapeutics for the treatment of HMC. J. Cell. Physiol. 232: 1650–1659, 2017.

Original languageEnglish
Pages (from-to)1650-1659
Number of pages10
JournalJournal of Cellular Physiology
Volume232
Issue number7
DOIs
Publication statusPublished - 1 Jul 2017
Externally publishedYes

Fingerprint

Cardiac Myosins
Hypertrophic Cardiomyopathy
Carrier Proteins
Genes
Mutation
Protein C
Inborn Genetic Diseases
Genetic Heterogeneity
Messenger RNA
Therapeutics
myosin-binding protein C

ASJC Scopus subject areas

  • Medicine(all)
  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

The Role of Cardiac Myosin Binding Protein C3 in Hypertrophic Cardiomyopathy-Progress and Novel Therapeutic Opportunities. / Mohamed, Iman A.; Krishnamoorthy, Navaneethakrishnan; Nasrallah, Gheyath K.; Da'as, Sahar.

In: Journal of Cellular Physiology, Vol. 232, No. 7, 01.07.2017, p. 1650-1659.

Research output: Contribution to journalReview article

@article{5f4b78a1d69e4407a35551d18a426b7e,
title = "The Role of Cardiac Myosin Binding Protein C3 in Hypertrophic Cardiomyopathy-Progress and Novel Therapeutic Opportunities",
abstract = "Hypertrophic cardiomyopathy (HCM) is a common autosomal dominant genetic cardiovascular disorder marked by genetic and phenotypic heterogeneity. Mutations in the gene encodes the cardiac myosin-binding protein C, cMYBPC3 is amongst the various sarcomeric genes that are associated with HCM. These mutations produce mutated mRNAs and truncated cMyBP-C proteins. In this review, we will discuss the implications and molecular mechanisms involved in MYBPC3 different mutations. Further, we will highlight the novel targets that can be developed into potential therapeutics for the treatment of HMC. J. Cell. Physiol. 232: 1650–1659, 2017.",
author = "Mohamed, {Iman A.} and Navaneethakrishnan Krishnamoorthy and Nasrallah, {Gheyath K.} and Sahar Da'as",
year = "2017",
month = "7",
day = "1",
doi = "10.1002/jcp.25639",
language = "English",
volume = "232",
pages = "1650--1659",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - The Role of Cardiac Myosin Binding Protein C3 in Hypertrophic Cardiomyopathy-Progress and Novel Therapeutic Opportunities

AU - Mohamed, Iman A.

AU - Krishnamoorthy, Navaneethakrishnan

AU - Nasrallah, Gheyath K.

AU - Da'as, Sahar

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Hypertrophic cardiomyopathy (HCM) is a common autosomal dominant genetic cardiovascular disorder marked by genetic and phenotypic heterogeneity. Mutations in the gene encodes the cardiac myosin-binding protein C, cMYBPC3 is amongst the various sarcomeric genes that are associated with HCM. These mutations produce mutated mRNAs and truncated cMyBP-C proteins. In this review, we will discuss the implications and molecular mechanisms involved in MYBPC3 different mutations. Further, we will highlight the novel targets that can be developed into potential therapeutics for the treatment of HMC. J. Cell. Physiol. 232: 1650–1659, 2017.

AB - Hypertrophic cardiomyopathy (HCM) is a common autosomal dominant genetic cardiovascular disorder marked by genetic and phenotypic heterogeneity. Mutations in the gene encodes the cardiac myosin-binding protein C, cMYBPC3 is amongst the various sarcomeric genes that are associated with HCM. These mutations produce mutated mRNAs and truncated cMyBP-C proteins. In this review, we will discuss the implications and molecular mechanisms involved in MYBPC3 different mutations. Further, we will highlight the novel targets that can be developed into potential therapeutics for the treatment of HMC. J. Cell. Physiol. 232: 1650–1659, 2017.

UR - http://www.scopus.com/inward/record.url?scp=85013243978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013243978&partnerID=8YFLogxK

U2 - 10.1002/jcp.25639

DO - 10.1002/jcp.25639

M3 - Review article

VL - 232

SP - 1650

EP - 1659

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 7

ER -